{"title":"Association between frailty and inflammatory cytokines in patients with multiple sclerosis: a case-control study","authors":"Shucheng Xing, Xue Li, Chen Chen","doi":"10.1016/j.cyto.2025.156945","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Frailty is a common symptom in Multiple Sclerosis (MS), yet its precise mechanism remains elusive, and the clinical implications of frailty in MS are uncertain. Moreover, inflammation is closely linked to frailty. This study aims to assess serum cytokine levels in individuals with MS and explore their correlation with frailty.</div></div><div><h3>Methods</h3><div>A case-control study included 83 primary MS patients and 100 healthy individuals undergoing health check-ups. Serum cytokine levels were measured, and MS severity was determined using the Expanded Disability Status Scale (EDSS) score. Additionally, a comprehensive frailty index (FI) was calculated based on health deficits from various domains following standardized procedures.</div></div><div><h3>Results</h3><div>Serum IL-6 and TNF-α levels were significantly higher in the frail group than in the non-frail group, with a statistically significant difference (<em>P</em> < 0.05). After adjusting for disease duration, sex, age, BMI, SBP, and DBP, serum IL-6 independently correlated with frailty in MS patients (OR = 1.46; 95 % CI = 1.02–1.93; <em>P</em> = 0.003). Moreover, increased serum IL-6 levels were associated positively with the frailty index (β = 0.123, <em>P</em> = 0.008).</div></div><div><h3>Conclusion</h3><div>Our initial findings suggest elevated levels of pro-inflammatory cytokines in MS patients with frailty, with IL-6 showing a positive correlation with frail indices. These results underscore the potential impact of inflammatory responses on frailty development in MS.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"191 ","pages":"Article 156945"},"PeriodicalIF":3.7000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466625000924","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Frailty is a common symptom in Multiple Sclerosis (MS), yet its precise mechanism remains elusive, and the clinical implications of frailty in MS are uncertain. Moreover, inflammation is closely linked to frailty. This study aims to assess serum cytokine levels in individuals with MS and explore their correlation with frailty.
Methods
A case-control study included 83 primary MS patients and 100 healthy individuals undergoing health check-ups. Serum cytokine levels were measured, and MS severity was determined using the Expanded Disability Status Scale (EDSS) score. Additionally, a comprehensive frailty index (FI) was calculated based on health deficits from various domains following standardized procedures.
Results
Serum IL-6 and TNF-α levels were significantly higher in the frail group than in the non-frail group, with a statistically significant difference (P < 0.05). After adjusting for disease duration, sex, age, BMI, SBP, and DBP, serum IL-6 independently correlated with frailty in MS patients (OR = 1.46; 95 % CI = 1.02–1.93; P = 0.003). Moreover, increased serum IL-6 levels were associated positively with the frailty index (β = 0.123, P = 0.008).
Conclusion
Our initial findings suggest elevated levels of pro-inflammatory cytokines in MS patients with frailty, with IL-6 showing a positive correlation with frail indices. These results underscore the potential impact of inflammatory responses on frailty development in MS.
期刊介绍:
The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
* Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors.
We will publish 3 major types of manuscripts:
1) Original manuscripts describing research results.
2) Basic and clinical reviews describing cytokine actions and regulation.
3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.